Truist Cuts Boston Scientific Corporation (BSX) Price Target but Maintains Buy After Earnings Pullback

Boston Scientific Corporation (NYSE:BSX) is included among 13 Best Long Term Low Risk Stocks to Buy Now.

On February 5, Truist lowered its terms nonsubjective connected Boston Scientific Corporation (NYSE:BSX) to $95 from $120. The steadfast maintained a Buy standing connected the stock. In a enactment to clients, the expert said the crisp pullback aft net appeared excessive, particularly with the banal present trading astatine a discount to faster-growing peers.

The absorption followed the company’s February 4 net release, which highlighted weaker-than-expected results successful the electrophysiology business. That unit, which focuses connected minimally invasive treatments for bosom bushed disorders, is simply a cardinal portion of Boston Scientific’s maturation narrative. Fourth-quarter income successful the conception reached $890 million, falling abbreviated of the $933 cardinal analysts had been expecting, according to RBC Capital Markets. The miss unsettled investors, who questioned whether maturation successful the conception was losing momentum. Citi expert Joanne Wuensch said those worries were justified.

Sales of the Watchman device, utilized to assistance forestall strokes successful patients with atrial fibrillation, besides came successful astir 1% beneath forecasts. Analysts attributed the shortfall chiefly to softer request successful the US market. For the twelvemonth ahead, Boston Scientific forecasts adjusted net per stock of $3.43 to $3.49. The midpoint of that scope landed conscionable nether Wall Street expectations of $3.47, based connected information from LSEG. On the quarter, gross totaled $5.29 cardinal and adjusted net were 80¢ per share, some astir successful enactment with estimates.

Looking further out, the institution expects integrated gross maturation of 10% to 11% successful 2026, pointing to a slower gait compared with the 15.8% integrated maturation reported successful 2025.

Boston Scientific Corporation (NYSE:BSX) develops and sells aesculapian devices utilized crossed a wide scope of interventional procedures astir the world.

While we admit the imaginable of BSX arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you’re looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 15 Best Wide Moat Dividend Stocks to Invest in and 12 Best HVAC Stocks to Buy Now

Disclosure: None.